Cerebrolysin in vascular dementia: Improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial

Journal of Stroke and Cerebrovascular Diseases

Volumn 20, Issue 4, 2011, Pages 310-318

  Guekht, Alla B ^a   Moessler, Herbert ^b   Novak, Philipp H ^b   Gusev, Evgenyi I ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Ebewe Neuro Pharma GmbH   (Austria)

Author keywords

Cerebrolysin; neurotrophic factors; RCT; Vascular dementia

Indexed keywords

ACETYLSALICYLIC ACID; CEREBROLYSIN;

ADD ON THERAPY; ADULT; AGED; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; AMINO ACIDS; ASPIRIN; CHI-SQUARE DISTRIBUTION; COGNITION; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; ODDS RATIO; PLACEBO EFFECT; PLATELET AGGREGATION INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960003564     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2010.01.012     Document Type: Article

References (32)

1. A.D. Korczyn Mixed dementia: The most common cause of dementia Ann NY Acad Sci 977 2002 129 134 (Pubitemid 35418145)
2. C. McVeigh, and P. Passmore Vascular dementia: Prevention and treatment Clin Interv Aging 1 2006 229 235
3. R. Hebert, and C. Brayne Epidemiology of vascular dementia Neuroepidemiology 14 1995 240 257
4. W. Rocca, and E. Kokmen Frequency and distribution of vascular dementia Alzheimer Dis Assoc Disord 13 Suppl 3 1999 9 14
5. E. Martinez-Vila, M. Murie-Fernandez, and J. Gallego Perez-Larraya Neuroprotection in vascular dementia Cerebrovasc Dis 21 Suppl 2 2006 106 117
6. H. Kavirajan, and L.S. Schneider Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials Lancet Neurol 6 2007 782 792 (Pubitemid 47243710)
7. A.D. Korczyn Drugs for vascular dementia Lancet Neurol 6 2007 749 755
8. N.V. Vereshchagin, E.M. Nekrasova, and N.V. Lebedeva Mild forms of multi-infarct dementia: Effectiveness of cerebrolysin Sov Med 11 1991 6 8
9. S. Duma Ambulante Behandlung cerebraler Funktionsstörungen Der Praktische Arzt 45 1991 1057 1062
10. T. Nishimura Comparative study on FPF 1070 (cerebrolysin) in patients with cerebrovascular dementia Shinyaku to Rinsho 42 1993 1113 1157
11. N. Yakhno, I. Damulin, and V. Zakharov High-dose cerebrolysin in vascular dementia Ter Arkh 68 1996 69 72
12. S. Xiao, H. Yan, and Y. Peifen A multi-center, double-blind, placebo-controlled trial of the efficacy of cerebrolysin in treatment of vascular dementia J Clin Psychol Med 9 1999 1 3
13. E. Ruether, X. Alvarez, and M. Rainer Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: A double-blind, placebo-controlled study with the neurotrophic agent cerebrolysin J Neural Transm Suppl 62 2002 265 275 (Pubitemid 37046670)
14. E. Ruether, R. Ritter, and M. Apecechea Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT) Pharmacopsychiatry 27 1994 32 40 (Pubitemid 24078987)
15. C. Bae, C. Cho, and K. Cho A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease J Am Geriatr Soc 48 2000 1566 1571
16. X. Alvarez, R. Cacabelos, and M. Laredo A 24-week, double-blind, placebo-controlled study of three dosages of cerebrolysin in patients with mild to moderate Alzheimer's disease Eur J Neurol 13 2006 43 54
17. E. Ruether, R. Husmann, and E. Kinzler A 28-week, double-blind, placebo-controlled study with cerebrolysin in patients with mild to moderate Alzheimer's disease Int Clin Psychopharmacol 16 2001 253 263 (Pubitemid 32822444)
18. D. Muresanu, X.A. Alvarez, and H. Moessler A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: Cognitive improvement correlates with qEEG acceleration J Neurol Sci 267 2008 112 119
19. G.C. Román, T.K. Tatemichi, and T. Erkinjuntti Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 43 1993 250 260 (Pubitemid 23060253)
20. L. Pantoni, and D. Inzitari Hachinski's ischemic score and the diagnosis of vascular dementia: A review Ital J Neurol Sci 14 1993 539 546
21. M. Hamilton Rating depressive patients J Clin Psychiatry 41 1980 21 24 (Pubitemid 11203735)
22. D.S. Knopman, M.J. Knapp, and S.I. Gracon The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease Neurology 44 1994 2315 2321
23. R.C. Mohs, D. Knopman, and R.C. Petersen Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 Suppl 2 1997 13 21
24. M. Folstein, S. Folstein, and P. McHugh "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
25. D. Galasko, D. Bennett, and M. Sano An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 Suppl 2 1975 33 39
26. W.D. Oswald, and U.M. Fleischmann Psychometrics in aging and dementia: Advances in geropsychological assessments Arch Gerontol Geriatr 4 1985 299 309 (Pubitemid 16170379)
27. D. Libon, R. Swenson, and E. Barnoski Clock drawing as an assessment tool for dementia Arch Clin Neuropsychol 8 1995 405 415
28. B. Kittner, P.P. De Deyn, and T. Erkinjunnti Investigating the natural course and treatment of vascular dementia and Alzheimer's disease: Parallel study populations in two randomized, placebo-controlled trials Ann NY Acad Sci 903 2000 535 541 (Pubitemid 30251600)
29. B.E. Wampold, T. Minami, and S.C. Tieney The placebo is powerful: Estimating placebo effects in medicine and psychotherapy from randomized clinical trials J Clin Psychol 61 2005 835 854 (Pubitemid 41153534)
30. F. Haour Mechanisms of the placebo effect and of conditioning Neuroimmunomodulation 12 2005 195 200 (Pubitemid 40910972)
31. T. Satou, T. Itoh, and M. Fujimoto Neurotrophic-like effects of FPF-1070 on cultured neurons from chick embryonic dorsal root ganglia Jpn J Pharmacol Ther 22 1994 205 212 (Pubitemid 24147732)
32. M.J. Schneck Vascular Dementia. Top Stroke Rehabil 15 2008 22 26